Skip to search formSkip to main contentSkip to account menu

ARN-509

Known as: Androgen Receptor Antagonist ARN-509 
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Thiohydantoins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines
Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to… 
2016
2016
The Ongoing Challenges of Targeting the Androgen Receptor.
2014
2014
A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial.
TPS5100 Background: ADT is the standard of care for patients (pts) with metastatic prostate cancer and is frequently used in pts… 
2014
2014
ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
5026 Background: ARN-509 is a second-generation antiandrogen that selectively binds to the ligand-binding domain of the androgen… 
2013
2013
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).
48 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the… 
2013
2013
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC).
7 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen… 
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate… 
2012
2012
A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).
4548 Background: ARN-509 is a novel small molecule AR antagonist that impairs AR nuclear translocation and binding to DNA… 
2012
2012
Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium…
43 Background: In CRPC, androgen receptor (AR) overexpression is associated with resistance to first-generation anti-androgen… 
2012
2012
Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium…
43 Background: In CRPC, androgen receptor (AR) overexpression is associated with resistance to first-generation anti-androgen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)